<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2026.1657719</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Systematic Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Visualizing research on the prognosis of papillary thyroid cancer: a bibliometric analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Pei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2772510/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Ming-Jun</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Mao</surname><given-names>Qiu-Fen</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Han</surname><given-names>Sheng-Bo</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Wen</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1864682/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Chao-Qun</given-names></name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhou</surname><given-names>Cong</given-names></name>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff9"><sup>9</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/552762/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Radiation Oncology, Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</institution>, <city>Luoyang</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Head and Neck Surgical Oncology, Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</institution>, <city>Luoyang</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Nuclear Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</institution>, <city>Luoyang</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff4"><label>4</label><institution>Jining Medical University Clinical College, Affiliated Hospital of Jining Medical University</institution>, <city>Jining</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff5"><label>5</label><institution>Department of Thyroid Surgery, Clinical Research Center for Thyroid Disease of Yunnan Province, The First Affiliated Hospital of Kunming Medical University</institution>, <city>Kunming</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff6"><label>6</label><institution>Tianjin Dongli District Centers for Disease Control and Prevention</institution>, <city>Tianjin</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff7"><label>7</label><institution>School of Mental Health, Jining Medical University</institution>, <city>Jining</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff8"><label>8</label><institution>Department of Psychology, Affiliated Hospital of Jining Medical University</institution>, <city>Jining</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff9"><label>9</label><institution>Center for Evidence-Based Medicine, Jining Medical University</institution>, <city>Jining</city>,&#xa0;<country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Cong Zhou, <email xlink:href="mailto:doctorzhoucong@163.com">doctorzhoucong@163.com</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-03-27">
<day>27</day>
<month>03</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1657719</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>03</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>04</day>
<month>03</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Wang, Wang, Mao, Han, Liu, Zhao and Zhou.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Wang, Wang, Mao, Han, Liu, Zhao and Zhou</copyright-holder>
<license>
<ali:license_ref start_date="2026-03-27">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Over the last two decades, the prognosis of papillary thyroid cancer (PTC) has attracted increasing research attention, highlighting its vital role in improving patient outcomes. However, despite the multitude of studies, comprehensive bibliometric analyses concentrating specifically on PTC prognosis are still scarce.</p>
</sec>
<sec>
<title>Methods</title>
<p>Our study involved a bibliometric analysis of 3,430 articles related to PTC prognosis, derived from the Web of Science Core Collection (WOSCC) database. We utilized VOSviewer, CiteSpace, and the R package &#x201c;bibliometrix&#x201d; to examine publication trends, identify key contributing countries and institutions, map collaborative networks, recognize prominent journals, and scrutinize both high-frequency keywords and highly cited references.</p>
</sec>
<sec>
<title>Results</title>
<p>From 2004 to 2024, the number of research articles on the prognosis of PTC steadily increased, with a total of 3,430 articles included in our analysis. The year 2022 marked the peak in the number of publications, with 325 articles being published. China and the United States are at the forefront in terms of publication volume and citations, albeit with a slightly lower citation rate for China. Notable contributions also emerge from South Korea, Italy, and Japan. Collaboration is predominantly observed among the leading nations, with developing countries engaging less frequently. Prominent institutions such as Kuma Hospital in Japan and Shanghai Jiao Tong University in China stand out in terms of publication output. The journals &#x201c;Thyroid,&#x201d; &#x201c;Frontiers in Endocrinology,&#x201d; and &#x201c;World Journal of Surgery&#x201d; lead the field, with &#x201c;Thyroid&#x201d; boasting the highest co-citation rate. The keyword analysis revealed six primary research clusters, focusing on cell and molecular biology, oncology-related terminology, risk factors, disease progression, and clinical treatment approaches. The highly cited articles underscore the significant impact of BRAF V600E mutations on PTC prognosis.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study offers an in-depth overview of prevailing research hotspots and trends, providing pivotal insights to direct future research endeavors and enhance prognostic care for PTC patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>bibliometric analysis</kwd>
<kwd>BRAF V600E</kwd>
<kwd>hotspots</kwd>
<kwd>papillary thyroid cancer</kwd>
<kwd>prognosis</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Henan Provincial Higher Education Research Project (2025SXHLX117), the Medical and Health Science and Technology Development Plan of Shandong Province (202203090679, 202304011343), the Key Research and Development Plan of Jining City (2021YXNS024, 2023JNZC141), the Cultivation Plan of High-level Scientific Research Projects of Jining Medical University (JYGC2021KJ006), and the Supporting Fund for Teachers&#x2019; Research of Jining Medical University (600903001).</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="6"/>
<equation-count count="0"/>
<ref-count count="36"/>
<page-count count="18"/>
<word-count count="8704"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Head and Neck Cancer</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Papillary thyroid cancer (PTC) is the most prevalent form of thyroid cancer, and the incidence of PTC is increasing in several countries (<xref ref-type="bibr" rid="B1">1</xref>). Classic PTC exhibits papillary structures and invasive nuclear features, with rare mitotic figures and common psammoma bodies, which are typically located in lymphatic vessels or stroma (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Patients with PTC may present with enlarged cervical lymph nodes. As the neck mass enlarges, it can compress and displace the trachea and esophagus, causing deformation. The high incidence and pronounced symptoms of PTC contribute to its increasing global burden. Nearly half of the global PTC burden is concentrated in South and East Asia. The burden of PTC in women is significantly greater than that in men and is also increasing annually (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Treatment options for PTC are diverse and can be broadly categorized into surgical and conservative approaches. Surgical treatment can be further divided into total thyroidectomy and&#xa0;more conservative thyroid lobectomy. In general, except for patients meeting the criteria for papillary thyroid microcarcinoma, most PTC patients are recommended for total thyroidectomy. This procedure can thoroughly remove the tumor, reduce the risk of recurrence, and decrease the need for reoperation. During surgery, prophylactic central compartment lymph node dissection is performed to minimize the degree of lymphatic spread of cancer cells. Studies indicate that for tumors larger than 1&#xa0;cm, the rate of local lymph node metastasis increases from 44.68% to 77.53% with increasing tumor size (<xref ref-type="bibr" rid="B6">6</xref>). These findings suggest that total thyroidectomy combined with central lymph node dissection is an aggressive and thorough treatment option, at least in the initial treatment stage. For patients with tumors smaller than 1&#xa0;cm, without extrathyroidal extension, and no clinically apparent lymph node metastasis, thyroid lobectomy can be considered. Additionally, conservative treatments for PTC include radiotherapy, chemotherapy, thermal ablation, radioactive iodine-131 therapy, and targeted drug therapies. While the overall prognosis for PTC patients is generally favorable, it varies significantly with the size of the primary tumor. Tumors confined to the thyroid, smaller than 1&#xa0;cm, or with micrometastases have a good prognosis. Conversely, distant metastasis and high invasiveness are associated with a poor prognosis (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Over the years, the guidelines for the treatment of thyroid cancer, particularly those from the American Thyroid Association (ATA) and the European Thyroid Association (ETA), have evolved significantly. A notable shift has been observed toward less aggressive surgical approaches, especially for low-risk differentiated thyroid cancers (DTC). For instance, the ATA guidelines have increasingly emphasized the importance of individualized treatment plans on the basis of risk stratification, suggesting the need for less extensive surgery in certain low-risk patients (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Similarly, the ETA guidelines also recommend more conservative surgical options for patients with small tumors and no evidence of extrathyroidal extension (<xref ref-type="bibr" rid="B9">9</xref>). These revisions reflect a growing understanding of the heterogeneity of thyroid cancers and the need for tailored treatment strategies to optimize outcomes while minimizing morbidity.</p>
<p>Our study focused on the prognosis of PTC patients to provide insights for future treatment strategies. Bibliometrics is a method that quantitatively analyzes the information contained in the literature using statistical and mathematical techniques to objectively assess research outcomes, identify research hotspots, and forecast emerging trends (<xref ref-type="bibr" rid="B10">10</xref>). Currently, bibliometric analysis is widely applied in thyroid disease research. Wang et&#xa0;al. systematically summarized the status and future prospects of thyroid cancer immunotherapy by analyzing relevant literature in the Web of Science database (<xref ref-type="bibr" rid="B11">11</xref>). Song et&#xa0;al. supplemented research on pediatric thyroid cancer via bibliometric methods (<xref ref-type="bibr" rid="B12">12</xref>). Chen et&#xa0;al. conducted a bibliometric analysis of maternal hypothyroidism (<xref ref-type="bibr" rid="B13">13</xref>). However, very few bibliometric studies have focused on the prognosis of PTC. Consequently, we aimed to conduct a bibliometric analysis to assess the developmental framework, present state, and future directions in the research area of PTC prognosis. Our goal was to elucidate the evolving trends and collaborative dynamics in PTC prognosis research, offering valuable insights for future investigations and clinical practices.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Data source and search strategy</title>
<p>In this study, all literature data were obtained from the Web of Science Core Collection database. This database encompasses academic publications from over 250 diverse global disciplinary fields and stands as a widely utilized platform for bibliometric analysis among research scholars (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). The bibliometric analysis in this article covers the period from January 1, 2004, to April 9, 2024. The search query employed was as follows: TS= (&#x201c;papillary thyroid carcinoma&#x201d; OR &#x201c;thyroid papillary carcinoma&#x201d; OR &#x201c;thyroid carcinoma, papillary&#x201d; OR &#x201c;papillary thyroid cancer&#x201d; OR &#x201c;thyroid papillary cancer&#x201d; OR &#x201c;thyroid cancer, papillary&#x201d;) AND TS= (Prognosis OR Prognoses OR Prognostic). Only English-language publications from the search results were included, and after excluding literature types such as letters, comments, and conference papers, a total of 3430 relevant articles were obtained. The detailed literature screening process is shown in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Flow chart illustrating the process of publication acquisition, filtering, and de-duplication for the bibliometric analysis of papillary thyroid cancer (PTC) prognosis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g001.tif">
<alt-text content-type="machine-generated">Flowchart illustrating the literature screening process for studies on papillary thyroid carcinoma prognosis, showing stages of exclusion by database, language, and document type, with reasons and article counts at each step. Four summary labels&#x2014;search strategy, database limited, language restriction, type restriction&#x2014;appear on the right.</alt-text>
</graphic></fig>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Data analysis</title>
<p>The study utilized various analysis tools, including Microsoft Office Excel 2021, VOSviewer (version 1.6.18), CiteSpace (version 6.1.R6), and the R package &#x201c;bibliometrix,&#x201d; for data analysis and visualization. Prior to analysis, we manually performed data cleaning and disambiguation to merge synonymous nodes and standardize author names and institutional affiliations (e.g., merging different spellings of the same institution, such as &#x201c;Shanghai Jiao Tong University&#x201d; and &#x201c;Shanghai Jiao Tong Univ&#x201d;) to ensure the accuracy of frequency counts and network linkages. Initially, data related to 1108 articles on papillary thyroid cancer (PTC) prognosis were uniformly extracted from the Web of Science Core Collection database, comprising information such as titles, authors, keywords, affiliations, countries/regions, citations, journals, and publication dates. This dataset underwent preliminary screening and processing before being analyzed via VOSviewer, CiteSpace, and the R package &#x201c;bibliometrix&#x201d; for bibliometric analysis. CiteSpace, known for creating knowledge maps in specific fields, was utilized for co-occurrence and clustering analysis of authors, research institutions, and countries (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). VOSviewer, a bibliometric analysis software, facilitates the extraction and analysis of key information from publications, including collaboration relationships among countries, authors, institutions, and co-occurrence patterns of keywords (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). For author and institution citation counts presented in <xref ref-type="table" rid="T1"><bold>Tables&#xa0;1</bold></xref>, <xref ref-type="table" rid="T2"><bold>2</bold></xref>, self-citations were not excluded, as retaining them provides a more comprehensive reflection of overall academic influence within the field, consistent with common practice in bibliometric analysis. Finally, Bibliometrix, an open-source R package, was employed for comprehensive bibliometric and scientometric analysis, particularly for analyzing evolving trends of keywords in the literature (<xref ref-type="bibr" rid="B21">21</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Ranking of the top ten major authors of PTC prognosis from 2004 to 2024.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Author</th>
<th valign="middle" align="center">Documents</th>
<th valign="middle" align="center">Total link strength</th>
<th valign="middle" align="center">Countries/regions</th>
<th valign="middle" align="left">institution</th>
<th valign="middle" align="left">Author</th>
<th valign="middle" align="left">Co- citations</th>
<th valign="middle" align="left">Total link strength</th>
<th valign="middle" align="left">Countries/regions</th>
<th valign="middle" align="left">institution</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Miyauchi, Akira</td>
<td valign="middle" align="center">81</td>
<td valign="middle" align="center">436</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Kuma Hospital</td>
<td valign="middle" align="left">Ito, Y</td>
<td valign="middle" align="center">1839</td>
<td valign="middle" align="center">18996</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Kuma Hospital</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Ito, Yasuhiro</td>
<td valign="middle" align="center">74</td>
<td valign="middle" align="center">426</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Kuma Hospital</td>
<td valign="middle" align="left">Xing, Mz</td>
<td valign="middle" align="center">1333</td>
<td valign="middle" align="center">16686</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">Johns Hopkins University</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Miya, Akihiro</td>
<td valign="middle" align="center">63</td>
<td valign="middle" align="center">408</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Kuma Hospital</td>
<td valign="middle" align="left">Haugen, Br</td>
<td valign="middle" align="center">943</td>
<td valign="middle" align="center">7836</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">University of Colorado</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Kihara, Minoru</td>
<td valign="middle" align="center">42</td>
<td valign="middle" align="center">288</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Waseda University</td>
<td valign="middle" align="left">Mazzaferri, El</td>
<td valign="middle" align="center">883</td>
<td valign="middle" align="center">10702</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">The Ohio State University</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Kobayashi, Kaoru</td>
<td valign="middle" align="center">42</td>
<td valign="middle" align="center">277</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Chiba University</td>
<td valign="middle" align="left">Hay, Id</td>
<td valign="middle" align="center">750</td>
<td valign="middle" align="center">8910</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">Mayo Clinic</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Takamura, Yuuki</td>
<td valign="middle" align="center">38</td>
<td valign="middle" align="center">281</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Kuma Hospital</td>
<td valign="middle" align="left">Cooper, Ds</td>
<td valign="middle" align="center">597</td>
<td valign="middle" align="center">6498</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">Johns Hopkins University</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Zhang, Hao</td>
<td valign="middle" align="center">37</td>
<td valign="middle" align="center">126</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="left">Jiangnan University</td>
<td valign="middle" align="left">Nikiforov, Ye</td>
<td valign="middle" align="center">519</td>
<td valign="middle" align="center">7437</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">University of Pittsburgh</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Higashiyama, Takuya</td>
<td valign="middle" align="center">35</td>
<td valign="middle" align="center">259</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="left">Kuma Hospital</td>
<td valign="middle" align="left">Davies, L</td>
<td valign="middle" align="center">516</td>
<td valign="middle" align="center">5883</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">Manchester Metropolitan University</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Ghossein, Ronald</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">45</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">Memorial Sloan Kettering Cancer Center</td>
<td valign="middle" align="left">Nikiforova, Mn</td>
<td valign="middle" align="center">442</td>
<td valign="middle" align="center">7200</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">University of Pittsburgh</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Tuttle, R. Michael</td>
<td valign="middle" align="center">29</td>
<td valign="middle" align="center">70</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">Memorial Sloan Kettering Cancer Center</td>
<td valign="middle" align="left">Jemal, A</td>
<td valign="middle" align="center">388</td>
<td valign="middle" align="center">2736</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="left">American Cancer Society</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Ranking of the top ten major institutions of PTC prognosis from 2004 to 2024.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Institution</th>
<th valign="middle" align="left">Publications</th>
<th valign="middle" align="left">Original country</th>
<th valign="middle" align="left">Institution</th>
<th valign="middle" align="left">Total link strength</th>
<th valign="middle" align="left">Original country</th>
<th valign="middle" align="left">Institution</th>
<th valign="middle" align="left">Citations</th>
<th valign="middle" align="left">Original country</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">1</td>
<td valign="middle" align="center">Kuma Hospital</td>
<td valign="middle" align="center">85</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="center">University of Pisa</td>
<td valign="middle" align="center">89</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">Johns Hopkins University</td>
<td valign="middle" align="center">5508</td>
<td valign="middle" align="center">USA</td>
</tr>
<tr>
<td valign="middle" align="center">2</td>
<td valign="middle" align="center">Yonsei University</td>
<td valign="middle" align="center">84</td>
<td valign="middle" align="center">South Korea</td>
<td valign="middle" align="center">Johns Hopkins University</td>
<td valign="middle" align="center">89</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">Memorial Sloan Kettering Cancer Center</td>
<td valign="middle" align="center">4912</td>
<td valign="middle" align="center">USA</td>
</tr>
<tr>
<td valign="middle" align="center">3</td>
<td valign="middle" align="center">Shanghai Jiao Tong University</td>
<td valign="middle" align="center">78</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">Memorial Sloan Kettering Cancer Center</td>
<td valign="middle" align="center">72</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">Kuma Hospital</td>
<td valign="middle" align="center">4645</td>
<td valign="middle" align="center">Japan</td>
</tr>
<tr>
<td valign="middle" align="center">4</td>
<td valign="middle" align="center">China Medical University</td>
<td valign="middle" align="center">73</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">Seoul National University</td>
<td valign="middle" align="center">69</td>
<td valign="middle" align="center">South Korea</td>
<td valign="middle" align="center">University of Pisa</td>
<td valign="middle" align="center">3748</td>
<td valign="middle" align="center">Italy</td>
</tr>
<tr>
<td valign="middle" align="center">5</td>
<td valign="middle" align="center">Sungkyunkwan University</td>
<td valign="middle" align="center">72</td>
<td valign="middle" align="center">South Korea</td>
<td valign="middle" align="center">University of Pittsburgh</td>
<td valign="middle" align="center">68</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">University of Ulsan</td>
<td valign="middle" align="center">2738</td>
<td valign="middle" align="center">South Korea</td>
</tr>
<tr>
<td valign="middle" align="center">6</td>
<td valign="middle" align="center">Zhejiang University</td>
<td valign="middle" align="center">72</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">University of Milan</td>
<td valign="middle" align="center">65</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">The University of Sydney</td>
<td valign="middle" align="center">2302</td>
<td valign="middle" align="center">Australia</td>
</tr>
<tr>
<td valign="middle" align="center">7</td>
<td valign="middle" align="center">Memorial Sloan Kettering Cancer Center</td>
<td valign="middle" align="center">64</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">University of Padua</td>
<td valign="middle" align="center">64</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">University of Pittsburgh</td>
<td valign="middle" align="center">2214</td>
<td valign="middle" align="center">USA</td>
</tr>
<tr>
<td valign="middle" align="center">8</td>
<td valign="middle" align="center">Fudan University</td>
<td valign="middle" align="center">62</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">University of Perugia</td>
<td valign="middle" align="center">61</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">University of Turin</td>
<td valign="middle" align="center">2204</td>
<td valign="middle" align="center">Italy</td>
</tr>
<tr>
<td valign="middle" align="center">9</td>
<td valign="middle" align="center">Sichuan University</td>
<td valign="middle" align="center">59</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">The University of Sydney</td>
<td valign="middle" align="center">59</td>
<td valign="middle" align="center">Australia</td>
<td valign="middle" align="center">University of Milan</td>
<td valign="middle" align="center">2149</td>
<td valign="middle" align="center">Italy</td>
</tr>
<tr>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">University of Ulsan</td>
<td valign="middle" align="center">57</td>
<td valign="middle" align="center">South Korea</td>
<td valign="middle" align="center">Zhejiang University</td>
<td valign="middle" align="center">48</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">University of Padua</td>
<td valign="middle" align="center">2051</td>
<td valign="middle" align="center">Italy</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Publication and citation analysis</title>
<p><xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2A</bold></xref> illustrates the upward trends in both publication and citation counts from 2004 to 2024. Both metrics consistently increased during this period. Significant increases in publications were observed in 2010, 2012, and 2020, with a peak of 325 publications per year in 2022. Similarly, citation counts experienced notable growth during 2011&#x2013;2014 and 2017-2020, likely attributed to influential publications preceding these periods. The highest citation peak, reaching 10,219 citations, was also recorded in 2022.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>The analysis of annual publication quantity and citation frequency in the field of PTC prognosis. <bold>(A)</bold> The annual publication quantity and citation frequency of research on PTC prognosis from 2004 to 2024. <bold>(B)</bold> The annual publication quantity, cumulative publication quantity, and their polynomial fitting curves for PTC prognosis from 2004 to 2024.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g002.tif">
<alt-text content-type="machine-generated">Panel A presents a combination bar and line graph showing the annual number of articles (blue bars, left y-axis) and citations (orange line, right y-axis) from 2004 to 2024, with articles increasing steadily and citations peaking in 2023 before sharply declining in 2024. Panel B provides another combination graph with articles per year as blue points and lines (left y-axis), total articles as orange bars (left y-axis), and a green line indicating cumulative total articles (right y-axis); both articles and total articles rise over time until a drop occurs in 2024.</alt-text>
</graphic></fig>
<p>Furthermore, a polynomial fit was applied to the cumulative annual publication count, as depicted in <xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2B</bold></xref>, with the fitting equation y=0.0774x<sup>3</sup>+7.2983x<sup>2</sup>-10.613x+68.36 and a fitting goodness of R&#xb2; = 0.9996.</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Countries/regions analysis</title>
<p>Analysis of countries/regions contributing to the PTC prognosis literature offers insights into the global distribution of research outcomes and focus areas (<xref ref-type="table" rid="T3"><bold>Table&#xa0;3</bold></xref>). China and the United States have emerged as key players in this field, leading in both article production and citation rates. While China has a significantly higher number of articles (1279) than other countries, the United States surpasses in total citation frequency (26,954), indicating potentially greater influence. Notable contributions are also observed from countries such as South Korea, Italy, and Japan, further enriching the research landscape in PTC prognosis.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Ranking of the top ten major countries/regions of PTC prognosis from 2004 to 2024.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Rank</th>
<th valign="middle" align="center">Countries</th>
<th valign="middle" align="center">Documents</th>
<th valign="middle" align="center">Countries</th>
<th valign="middle" align="center">Total link strength</th>
<th valign="middle" align="center">Countries</th>
<th valign="middle" align="center">Citations</th>
<th valign="middle" align="center">Countries</th>
<th valign="middle" align="center">H-index</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">1</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">1279</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">297</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">26954</td>
<td valign="middle" align="center">Spain</td>
<td valign="middle" align="center">40</td>
</tr>
<tr>
<td valign="middle" align="center">2</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">544</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">190</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">17285</td>
<td valign="middle" align="center">Australia</td>
<td valign="middle" align="center">38</td>
</tr>
<tr>
<td valign="middle" align="center">3</td>
<td valign="middle" align="center">South Korea</td>
<td valign="middle" align="center">440</td>
<td valign="middle" align="center">China</td>
<td valign="middle" align="center">140</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">13501</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">34</td>
</tr>
<tr>
<td valign="middle" align="center">4</td>
<td valign="middle" align="center">Italy</td>
<td valign="middle" align="center">266</td>
<td valign="middle" align="center">Spain</td>
<td valign="middle" align="center">85</td>
<td valign="middle" align="center">South Korea</td>
<td valign="middle" align="center">11941</td>
<td valign="middle" align="center">Sweden</td>
<td valign="middle" align="center">33</td>
</tr>
<tr>
<td valign="middle" align="center">5</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="center">211</td>
<td valign="middle" align="center">Australia</td>
<td valign="middle" align="center">80</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="center">9076</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">33</td>
</tr>
<tr>
<td valign="middle" align="center">6</td>
<td valign="middle" align="center">Turkey</td>
<td valign="middle" align="center">109</td>
<td valign="middle" align="center">Canada</td>
<td valign="middle" align="center">78</td>
<td valign="middle" align="center">Spain</td>
<td valign="middle" align="center">4137</td>
<td valign="middle" align="center">Canada</td>
<td valign="middle" align="center">31</td>
</tr>
<tr>
<td valign="middle" align="center">7</td>
<td valign="middle" align="center">Brazil</td>
<td valign="middle" align="center">93</td>
<td valign="middle" align="center">Germany</td>
<td valign="middle" align="center">65</td>
<td valign="middle" align="center">Australia</td>
<td valign="middle" align="center">3921</td>
<td valign="middle" align="center">France</td>
<td valign="middle" align="center">29</td>
</tr>
<tr>
<td valign="middle" align="center">8</td>
<td valign="middle" align="center">Germany</td>
<td valign="middle" align="center">70</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="center">64</td>
<td valign="middle" align="center">Canada</td>
<td valign="middle" align="center">2813</td>
<td valign="middle" align="center">Japan</td>
<td valign="middle" align="center">29</td>
</tr>
<tr>
<td valign="middle" align="center">9</td>
<td valign="middle" align="center">Australia</td>
<td valign="middle" align="center">69</td>
<td valign="middle" align="center">Poland</td>
<td valign="middle" align="center">63</td>
<td valign="middle" align="center">Poland</td>
<td valign="middle" align="center">2557</td>
<td valign="middle" align="center">Poland</td>
<td valign="middle" align="center">26</td>
</tr>
<tr>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">Poland</td>
<td valign="middle" align="center">65</td>
<td valign="middle" align="center">Czech Republic</td>
<td valign="middle" align="center">60</td>
<td valign="middle" align="center">Germany</td>
<td valign="middle" align="center">2530</td>
<td valign="middle" align="center">England</td>
<td valign="middle" align="center">24</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Using VOSviewer, we performed an extensive analysis of countries/regions. The collaboration dynamics among these nations are depicted in <xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref> via a chord diagram, with each country represented by differently colored ribbons reflecting collaboration strength. The findings highlight China as a leader in global collaboration, closely followed by the United States. Strong collaboration is observed between these two nations and between the United States and Italy. South Korea also plays a significant role in fostering academic exchanges, particularly with the United States.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>National collaborative network mapping of PTC prognosis from 2004 to 2024.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g003.tif">
<alt-text content-type="machine-generated">Chord diagram illustrating international connections among twenty-six countries or regions, with colored arcs representing each country and curved lines of varying thickness showing the volume of interactions or relationships between them.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Author analysis</title>
<p><xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref> presents the top ten authors on the basis of publication count and total co-citations. Leading contributors such as Miyauchi, Akira, Ito, Yasuhiro, Miya, and Akihiro have each authored over 50 publications in the field, notably all affiliated with Kuma Hospital in Japan. Regional diversity is evident among the top authors by publication count, with representations from South Korea, Japan, the USA, and China, which is consistent with the analysis of research dominance among countries/regions. Notably, the majority of authors with the highest total co-citations are from the USA, with only one exception from South Korea. Authors from institutions such as Johns Hopkins University and the University of Pittsburgh stand out among the top contributors.</p>
<p>To further illustrate the connections among these authors and their potential research similarities, the results of the analysis using VOSviewer are presented in <xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref>. In <xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4A</bold></xref>, different colors distinguish several major clusters, visualizing the collaboration relationships between authors within the same cluster. In <xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4A</bold></xref>, the largest author collaboration cluster, represented in green, centers around authors from Kuma Hospital in Japan, such as Miyauchi, Akira and Miya, Akihiro. Another significant cluster, shown in purple on the left, mainly includes authors from the University of Ulsan in South Korea, such as Chung, Ki-Wook and Kim, Won Bae. Various clusters of South Korean authors are visible, indicating geographical proximity and interconnectivity among them. Another notable cluster, highlighted in orange, primarily consists of Chinese authors, whereas the yellow cluster represents collaboration among American authors. Geographical proximity plays a role in author collaboration, but international collaboration is also significant, as seen in the red cluster with multinational collaboration, including authors from Italy, the USA, and Australia. Overall, the distribution of author collaboration clusters reveals spatial patterns, with most collaborations occurring among authors from the same country or institution, resulting in relatively independent clusters with minimal connections between them.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Author collaborative and citation network mapping of PTC prognosis from 2004 to 2024. <bold>(A)</bold> The map visualizes co-occurring authors in PTC prognosis research, with nodes of different colors reflecting authors in distinct clusters. Node size signifies the frequency of co-occurrence, and the links represent the co-occurrence relationships among authors. <bold>(B)</bold> The map visualizes co-cited authors in PTC prognosis research, where the node size corresponds to the frequency of their citations. This information is presented using VOSViewer to succinctly capture and analyze the interconnectedness of cited authors in the PTC prognosis research landscape.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g004.tif">
<alt-text content-type="machine-generated">Two network diagrams labeled A and B display clusters of interconnected researchers, with each cluster represented by different colors and node sizes indicating varying levels of centrality or collaboration. Diagram A features smaller, distinct groups while diagram B shows larger networks with denser interconnections, highlighting key figures such as Miyauchi Akira, Xing MZ, Haugen BR, Ito Y, and Mazzaferri EL as central nodes within their respective clusters.</alt-text>
</graphic></fig>
<p><xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4B</bold></xref> provides a visual representation of co-citation relationships between authors, indicating how frequently two authors are cited together by third-party authors in the same publication. This indirect co-citation relationship offers insights into potential connections and research relevance between these authors. While authors in this field cover a broad range of research topics, including neuroscience and the respiratory system, there are also more focused research directions within this broader scope. The authors are mainly divided into four clusters distinguished by color. In the red cluster on the right, the emphasis is primarily on clinical and surgical aspects. Authors such as Ito, Yasuhiro, Haugen, Br, Mazzaferri, El, and Davies, L have made significant contributions in this direction. The green cluster on the left predominantly focuses on cellular and molecular biology, featuring authors such as Xing, Mingzhao, Nikiforov, Ye, and Elisei, Rossella. Authors in the blue cluster in the middle primarily engage in pathology, laboratory medicine, or experimental medicine, including Baloch, Zubair W., Rosai, Juan, and Livolsi, V. A. The yellow cluster at the bottom encompasses authors with more diverse research directions, yet their studies also exhibit common themes in endocrinology, metabolism, and oncology.</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Institution analysis</title>
<p><xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref> presents the top ten institutions in terms of the number of publications, total link strength, and total citations. Kuma Hospital in Japan has emerged as the most prolific institution in output in the field of PTC prognosis, with 85 publications, and it also ranks among the top three in terms of total citations (4645). The second most common institution is Yonsei University in South Korea, with 84 publications, while three institutions from China&#x2014;Shanghai Jiao Tong University (78 publications), China Medical University (73 publications), and Zhejiang University (72 publications)&#x2014;also make significant contributions to PTC prognosis research. Notably, Johns Hopkins University in the USA stands out as the institution with the highest number of total citations (5508), followed by Memorial Sloan Kettering Cancer Center (4912).</p>
<p><xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5</bold></xref> provides a visual representation of collaborative relationships among institutions, illustrating the spatial distribution of these collaborations. In <xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5A</bold></xref>, the upper left green cluster primarily gathers South Korean institutions with close collaborative ties, including several institutions that have made significant contributions to the field, such as Sungkyunkwan University, Seoul National University, and Yonsei University. The pink and red clusters on the right exhibit greater diversity in regions, predominantly featuring institutions from Europe and the USA, including Karolinska University Hospital in Sweden and the University of Porto in Portugal, as well as renowned American universities or medical centers such as Harvard Medical School, Memorial Sloan Kettering Cancer Center, and University of Texas MD Anderson Cancer Center. Although the brown cluster comprises fewer institutions, the University of Pisa, which has the strongest total link strength, is included in this cluster. Additionally, other Italian institutions such as the University of Naples Federico II and University of Padua are also present. The purple, yellow, and dark blue clusters at the bottom represent institutions in China, including influential institutions such as Shanghai Jiao Tong University, Zhejiang University, Huazhong University of Science and Technology, and Sun Yat-sen University. While the light blue and orange clusters also include Chinese institutions, they mainly depict multinational collaborations, such as academic exchanges between Kuma Hospital in Japan and Shandong University, and between the University of Sydney and the University of Milan.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Institutional collaborative network mapping of PTC prognosis from 2004 to 2024. <bold>(A)</bold> The co-occurrence graph of research institutions is displayed, where node size indicates the frequency of co-occurrence, and connections represent the co-occurrence relationships. The size of each node reflects how often research institutions appear together, while the links signify the instances of their collaborative occurrences. <bold>(B)</bold> The figure depicts institutions&#x2019; recent contributions to PTC prognosis research relative to their overall output from 2004 to 2024, with a red bias indicating increased influence and a blue bias suggesting decreased activity in the field. The color scale reflects the ratio of keywords over the past five years, highlighting institutions with notable impacts or reduced involvement in this study.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g005.tif">
<alt-text content-type="machine-generated">Panel A shows a network diagram of institutional collaborations in thyroid research, grouped by color representing clusters of collaborating institutions. Panel B presents the same network, with nodes and edges color-coded according to the average year of collaboration, ranging from blue for earlier years (2014) to red for more recent years (2020), as indicated by the color bar in the lower right corner.</alt-text>
</graphic></fig>
<p><xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5B</bold></xref>, which extends the spatial analysis in <xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5A</bold></xref>, introduces a temporal dimension by examining the frequency of collaboration over the past five years. The color scheme highlights the chronological sequence of collaboration relationships on the basis of their occurrence frequency. This reveals that in the early years of this century, research on PTC prognosis was primarily conducted by institutions from Japan, South Korea, Europe, and the USA, with establishments such as Kuma Hospital and the University of Texas MD Anderson Cancer Center laying a solid foundation for the future development of this field. However, in recent years, there has been a noticeable shift, with academic collaboration among institutions in China injecting new vitality into this field.</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Journal analysis</title>
<p><xref ref-type="table" rid="T4"><bold>Table&#xa0;4</bold></xref> presents the top ten journals in terms of the number of publications and citations in this field. The journal with the highest number of publications is <italic>Thyroid</italic> (173 articles), which also has the highest citation count (9121 citations). Following <italic>Thyroid</italic>, we have <italic>Frontiers in Endocrinology</italic> (92 articles), <italic>World Journal of Surgery</italic> (85 articles), and <italic>Cancers</italic> (83 articles). The journals with the second highest citation count are <italic>Journal of Clinical Endocrinology and Metabolism</italic> (7532 citations) and <italic>World Journal of Surgery</italic> (3815 citations), indicating their central role in this field. More than half of the journals listed in the top rankings for both publication and citation frequency are high-impact journals in the Q1 or Q2 category. Given that the impact factor is an important indicator of journal quality, it can be inferred that articles on PTC prognosis published in these journals maintain a high level of quality.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Ranking of the top ten major journals of PTC prognosis from 2004 to 2024.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Journal</th>
<th valign="middle" align="left">Publications</th>
<th valign="middle" align="left">IF(JCR2022)</th>
<th valign="middle" align="left">JCR quartile</th>
<th valign="middle" align="left">Co-Cited-Journal</th>
<th valign="middle" align="left">Citations</th>
<th valign="middle" align="left">IF(JCR2022)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="center">Thyroid</td>
<td valign="middle" align="center">173</td>
<td valign="middle" align="center">6.6</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="center">Thyroid</td>
<td valign="middle" align="center">9121</td>
<td valign="middle" align="center">6.6</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="center">Frontiers in Endocrinology</td>
<td valign="middle" align="center">92</td>
<td valign="middle" align="center">5.2</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="center">Journal of Clinical Endocrinology and Metabolism</td>
<td valign="middle" align="center">7532</td>
<td valign="middle" align="center">5.8</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="center">World Journal of Surgery</td>
<td valign="middle" align="center">85</td>
<td valign="middle" align="center">2.6</td>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="center">World Journal of Surgery</td>
<td valign="middle" align="center">3815</td>
<td valign="middle" align="center">2.6</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="center">Cancers</td>
<td valign="middle" align="center">83</td>
<td valign="middle" align="center">5.2</td>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="center">Surgery</td>
<td valign="middle" align="center">3656</td>
<td valign="middle" align="center">3.8</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="center">Journal of Clinical Endocrinology and Metabolism</td>
<td valign="middle" align="center">75</td>
<td valign="middle" align="center">5.8</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="center">Cancer</td>
<td valign="middle" align="center">2408</td>
<td valign="middle" align="center">6.2</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="center">Annals of Surgical Oncology</td>
<td valign="middle" align="center">66</td>
<td valign="middle" align="center">3.7</td>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="center">Annals of Surgical Oncology</td>
<td valign="middle" align="center">2403</td>
<td valign="middle" align="center">3.7</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="center">Frontiers in Oncology</td>
<td valign="middle" align="center">63</td>
<td valign="middle" align="center">4.7</td>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="center">Cancer Research</td>
<td valign="middle" align="center">2198</td>
<td valign="middle" align="center">4.6</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="center">Medicine</td>
<td valign="middle" align="center">57</td>
<td valign="middle" align="center">1.6</td>
<td valign="middle" align="left">Q3</td>
<td valign="middle" align="center">Endocr-Relat Cancer</td>
<td valign="middle" align="center">2073</td>
<td valign="middle" align="center">3.9</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="center">Endocrine</td>
<td valign="middle" align="center">54</td>
<td valign="middle" align="center">3.7</td>
<td valign="middle" align="left">Q3</td>
<td valign="middle" align="center">Clinical Endocrinology</td>
<td valign="middle" align="center">1749</td>
<td valign="middle" align="center">3.2</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="center">Endocrine Journal</td>
<td valign="middle" align="center">53</td>
<td valign="middle" align="center">2</td>
<td valign="middle" align="left">Q4</td>
<td valign="middle" align="center">Oncogene</td>
<td valign="middle" align="center">1516</td>
<td valign="middle" align="center">8</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The citation and collaboration relationships among these journals are visually depicted in <xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6A</bold></xref>, offering a more intuitive understanding of their interactions. <italic>Thyroid</italic> prominently emerges as a core journal in the field and is closely linked to <italic>World Journal of Surgery</italic>, <italic>Surgery</italic>, and <italic>Endocrine Journal</italic>. <xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6B</bold></xref> visualizes the research domains represented by these journals through distinct colored clusters. For example, journals focusing on medicine and surgery, such as the <italic>Journal of Clinical Endocrinolo</italic>gy and Metabolism, <italic>Surgery</italic>, and <italic>World Journal of Surgery</italic>, are grouped in the green cluster. Journals covering research content in the fields of molecular biology, cell biology, and pathology, such as <italic>Acta Cytologica</italic>, <italic>Cancer Cytopathology</italic>, <italic>Endocrine Pathology</italic>, and <italic>The Journal of Pathology</italic>, are clustered in the blue category. Journals related to cancer research or endocrinology, including <italic>Endocrine-Related Cancer</italic>, <italic>Oncotarget</italic>, and <italic>CA: A Cancer Journal for Clinicians</italic>, are highlighted in the red or yellow clusters.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Journal citation network mapping of PTC prognosis from 2004 to 2024. <bold>(A)</bold> The VOSviewer visualization examines collaborative relationships among journals, with nodes representing journals publishing over ten documents and colored according to their cluster membership. Node size reflects the frequency of these journals&#x2019; presence in the network. <bold>(B)</bold> The VOSviewer visualization enables exploration of connections between journals, with node size indicating the frequency of citations and reflecting the significance and influence of the journals in the network. <bold>(C)</bold> The dual-map of PTC prognosis research journals is presented, with the left side depicting clusters of citing journals and the right side representing the cited journals. The colored trajectories between them indicate the citation relationships.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g006.tif">
<alt-text content-type="machine-generated">Three network diagrams labeled A, B, and C, each displaying interconnected nodes and clusters in various colors representing relationships among scientific journals or research fields, with notable clusters labeled &#x201c;Thyroid,&#x201d; &#x201c;Journal of Clinical Endocrinology &amp; Metabolism,&#x201d; &#x201c;Surgery,&#x201d; and &#x201c;Molecular Biology, Immunology.&#x201d; Arrows and lines indicate citation flows or field linkages, and each panel visualizes structure and interactions within scientific literature or disciplines.</alt-text>
</graphic></fig>
<p><xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6C</bold></xref> provides additional clarification on the citation and co-citation relationships among journals through an overlay analysis obtained using CiteSpace. The citing journals are listed on the right, whereas the cited journals are listed on the left. The thickness of the lines between them indicates the strength of the citation relationship. It is apparent that the citing journals primarily originate from fields such as medicine, molecular biology, immunology, and clinical studies, whereas the cited journals predominantly belong to domains such as molecular genetics, health, and medicine.</p>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Keywords analysis</title>
<p><xref ref-type="table" rid="T5"><bold>Table&#xa0;5</bold></xref> presents the top 20 keywords based on occurrence frequency and total link strength, which represent the main directions or core viewpoints of the research and can accurately reflect the research hotspots and frontiers in the field during a specific time period. The most frequently occurring keyword is papillary thyroid carcinoma (1845 occurrences), followed by thyroid cancer (524 occurrences) and prognosis (444 occurrences). Additionally, there are keywords related to the pathological manifestations and treatment targets of PTC, such as lymph node metastasis, biomarker, and BRAF V600E.</p>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>Ranking of the top twenty major keywords of PTC prognosis from 2004 to 2024.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Keyword</th>
<th valign="middle" align="left">Occurrences</th>
<th valign="middle" align="left">Total link strength</th>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Keyword</th>
<th valign="middle" align="left">Occurrences</th>
<th valign="middle" align="left">Total link strength</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">1</td>
<td valign="middle" align="center">papillary thyroid carcinoma</td>
<td valign="middle" align="center">1845</td>
<td valign="middle" align="center">2769</td>
<td valign="middle" align="center">11</td>
<td valign="middle" align="center">differentiated thyroid cancer</td>
<td valign="middle" align="center">81</td>
<td valign="middle" align="center">159</td>
</tr>
<tr>
<td valign="middle" align="center">2</td>
<td valign="middle" align="center">thyroid cancer</td>
<td valign="middle" align="center">524</td>
<td valign="middle" align="center">857</td>
<td valign="middle" align="center">12</td>
<td valign="middle" align="center">cancer</td>
<td valign="middle" align="center">80</td>
<td valign="middle" align="center">161</td>
</tr>
<tr>
<td valign="middle" align="center">3</td>
<td valign="middle" align="center">prognosis</td>
<td valign="middle" align="center">444</td>
<td valign="middle" align="center">911</td>
<td valign="middle" align="center">13</td>
<td valign="middle" align="center">immunohistochemistry</td>
<td valign="middle" align="center">77</td>
<td valign="middle" align="center">128</td>
</tr>
<tr>
<td valign="middle" align="center">4</td>
<td valign="middle" align="center">braf</td>
<td valign="middle" align="center">170</td>
<td valign="middle" align="center">378</td>
<td valign="middle" align="center">14</td>
<td valign="middle" align="center">lymph node</td>
<td valign="middle" align="center">68</td>
<td valign="middle" align="center">178</td>
</tr>
<tr>
<td valign="middle" align="center">5</td>
<td valign="middle" align="center">lymph node metastasis</td>
<td valign="middle" align="center">163</td>
<td valign="middle" align="center">378</td>
<td valign="middle" align="center">15</td>
<td valign="middle" align="center">radioactive iodine</td>
<td valign="middle" align="center">65</td>
<td valign="middle" align="center">150</td>
</tr>
<tr>
<td valign="middle" align="center">6</td>
<td valign="middle" align="center">thyroid</td>
<td valign="middle" align="center">156</td>
<td valign="middle" align="center">304</td>
<td valign="middle" align="center">16</td>
<td valign="middle" align="center">follicular thyroid cancer</td>
<td valign="middle" align="center">62</td>
<td valign="middle" align="center">173</td>
</tr>
<tr>
<td valign="middle" align="center">7</td>
<td valign="middle" align="center">recurrence</td>
<td valign="middle" align="center">155</td>
<td valign="middle" align="center">349</td>
<td valign="middle" align="center">17</td>
<td valign="middle" align="center">lncrna</td>
<td valign="middle" align="center">58</td>
<td valign="middle" align="center">108</td>
</tr>
<tr>
<td valign="middle" align="center">8</td>
<td valign="middle" align="center">braf v600e</td>
<td valign="middle" align="center">121</td>
<td valign="middle" align="center">220</td>
<td valign="middle" align="center">18</td>
<td valign="middle" align="center">nomogram</td>
<td valign="middle" align="center">58</td>
<td valign="middle" align="center">122</td>
</tr>
<tr>
<td valign="middle" align="center">9</td>
<td valign="middle" align="center">metastasis</td>
<td valign="middle" align="center">116</td>
<td valign="middle" align="center">242</td>
<td valign="middle" align="center">19</td>
<td valign="middle" align="center">survival</td>
<td valign="middle" align="center">58</td>
<td valign="middle" align="center">143</td>
</tr>
<tr>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">biomarker</td>
<td valign="middle" align="center">92</td>
<td valign="middle" align="center">211</td>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">microrna</td>
<td valign="middle" align="center">57</td>
<td valign="middle" align="center">132</td>
</tr>
</tbody>
</table>
</table-wrap>
<p><xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7A, B</bold></xref> depict the co-occurrence relationships and strengths among key terms, not only reflecting the overlap of research content but also aiding in the identification of potential connections between research topics and paradigms. This is valuable for researchers to explore new research directions. As shown in <xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7A</bold></xref>, the key term with the highest co-occurrence strength is papillary thyroid carcinoma, which is located at the center. It forms a red cluster with some terms related to cell biology and molecular biology on the right, such as microRNA, proliferation, apoptosis, and biomarker. The yellow cluster below mainly consists of terms related to cancer, such as TCGA (The Cancer Genome Atlas), anaplastic thyroid carcinoma, follicular thyroid cancer, etc. The orange cluster mainly lists terms related to risk factors and disease progression of PTC, such as risk factors, lateral node metastasis, risk stratification, etc. The keywords in the deep blue and light blue clusters located at the bottom left are mainly related to clinical medicine and surgery, such as thyroidectomy, radioactive iodine, surgery. The keywords in the green cluster focus on describing the pathological manifestations of PTC and clinical or laboratory diagnostic methods, such as pathology, ultrasonography, fine-needle aspiration, etc. The purple cluster displays some terms related to cell biology or molecular biology related to PTC, such as immunohistochemistry, BRAF V600E, etc. <xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7B</bold></xref> includes a description of the contribution strength of keywords. It is evident that in recent years, the high-temperature keywords mainly describe nouns related to oncology, such as anaplastic thyroid carcinoma, follicular thyroid cancer, medullary thyroid carcinoma, etc.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Keywords co-occurrence network mapping of PTC prognosis from 2004 to 2024. <bold>(A)</bold> The keyword map of PTC prognosis research visually displays the connections among studied keywords. Nodes, distinguished by various colors, represent different keyword clusters. Node size reflects co-occurrence frequency, and connections between nodes depict relationships among keywords. <bold>(B)</bold> The figure depicts institutions&#x2019; recent contributions to PTC prognosis research relative to their overall output from 2004 to 2024, with a red bias indicating increased influence and a blue bias suggesting decreased activity in the field. The color scale reflects the ratio of keywords over the past five years, highlighting institutions with notable impacts or reduced involvement in this study. <bold>(C)</bold> The diagram illustrates the 25 primary keywords characterized by pronounced bursts of citations, denoted by red spikes on the timeline. These spikes signify sudden surges in citation counts, signaling pivotal moments of emerging crucial questions or solutions within the field.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g007.tif">
<alt-text content-type="machine-generated">Two network diagrams labeled A and B visualize keyword co-occurrence patterns for papillary thyroid carcinoma research, highlighting clusters and interconnections. Panel C presents a horizontal bar graph listing the top twenty-five keywords with the strongest citation bursts in this field from 2004 to 2024, showing each keyword, its burst strength, and the activity duration in red bars against a yearly timeline.</alt-text>
</graphic></fig>
<p><xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7C</bold></xref> presents the top 25 keywords exhibiting the most robust citation bursts. The keywords with the highest burst strengths are prognostic factors (34.18) and high prevalence (23.06), indicating their early emergence as research hotspots. The keyword with the longest duration of sustained research interest is differentiated carcinoma (2004-2015). Below, there are also several keywords still experiencing bursts, demonstrating that research on these topics remains current hotspots, such as guidelines (13.14), association guidelines (12.84), PTC (papillary thyroid carcinoma) (12.26), and case report (8.91).</p>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>Highly cited references analysis</title>
<p>The citation count is an important indicator for assessing the quality and impact of articles. Highly cited articles play a crucial role in driving research progress and reflecting research trends. <xref ref-type="table" rid="T6"><bold>Table&#xa0;6</bold></xref> presents basic information on the top fifteen highly cited articles, with the highest citation count attributed to the review by Prahallad, A et&#xa0;al., published in 2012 in <italic>Nature</italic>, titled &#x201c;Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR&#x201d; (<xref ref-type="bibr" rid="B22">22</xref>) (1499 citations). This article primarily addresses the issue of the poor efficacy of the drug PL4032 in patients with BRAF (V600E) mutant colorectal cancer. It analyzes the causes and mechanisms of action of BRAF (V600E), proposing a combination therapy using BRAF and EGFR inhibitors was proposed to treat patients with BRAF (V600E) mutant colorectal cancer. The second most highly cited literature, with 764 citations, is the article titled &#x201c;BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer&#x201d; (<xref ref-type="bibr" rid="B23">23</xref>) authored by Xing, MZ et&#xa0;al. and published in the <italic>Journal of Clinical Endocrinology and Metabolism</italic> in 2005. Given the early publication of this article, we can infer that its research findings laid the groundwork for many subsequent studies. Through a multicenter study, this study explored the associations between BRAF mutations and the occurrence of extrathyroidal invasion, lymph node metastasis, and advanced tumor stages III/IV in patients with PTC. These findings underscore the importance of BRAF in disease diagnosis, progression, and its potential role as a therapeutic target. In the third article, also authored by Xing, MZ et&#xa0;al. and published in 2013 in <italic>JAMA - Journal of the American Medical Association</italic>, titled &#x201c;Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer&#x201d; (<xref ref-type="bibr" rid="B24">24</xref>), the author further investigated the impact of BRAF on patients with PTC. Through a retrospective multicenter study, they reported an association between the BRAF (V600E) mutation and increased mortality in patients with PTC, highlighting the significant regulatory role of BRAF in the prognosis of PTC patients.</p>
<table-wrap id="T6" position="float">
<label>Table&#xa0;6</label>
<caption>
<p>Ranking of the top fifteen major highly cited references of PTC prognosis from 2004 to 2024.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Author</th>
<th valign="middle" align="left">Article title</th>
<th valign="middle" align="left">Source title</th>
<th valign="middle" align="left">Cited</th>
<th valign="middle" align="left">Year</th>
<th valign="middle" align="left">Category</th>
<th valign="middle" align="left">DOI</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Prahallad, A; Sun, C; Huang, SD; Di Nicolantonio, F; Salazar, R; Zecchin, D; Beijersbergen, RL; Bardelli, A; Bernards, R</td>
<td valign="middle" align="left">Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</td>
<td valign="middle" align="left">NATURE</td>
<td valign="middle" align="left">1499</td>
<td valign="middle" align="left">2012</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1038/nature10868</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Xing, MZ; Westra, WH; Tufano, RP; Cohen, Y; Rosenbaum, E; Rhoden, KJ; Carson, KA; Vasko, V; Larin, A; Tallini, G; Tolaney, S; Holt, EH; Hui, P; Umbricht, CB; Basaria, S; Ewertz, M; Tufaro, AP; Califano, JA; Ringel, MD; Zeiger, MA; Sidransky, D; Ladenson, PW</td>
<td valign="middle" align="left">BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer</td>
<td valign="middle" align="left">JOURNAL OF CLINICAL ENDOCRINOLOGY &amp; METABOLISM</td>
<td valign="middle" align="left">764</td>
<td valign="middle" align="left">2005</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1210/jc.2005-0987</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Xing, MZ; Alzahrani, AS; Carson, KA; Viola, D; Elisei, R; Bendlova, B; Yip, L; Mian, C; Vianello, F; Tuttle, RM; Robenshtok, E; Fagin, JA; Puxeddu, E; Fugazzola, L; Czarniecka, A; Jarzab, B; O&#x2019;Neill, CJ; Sywak, MS; Lam, AK; Riesco-Eizaguirre, G; Santisteban, P; Nakayama, H; Tufano, RP; Pai, SI; Zeiger, MA; Westra, WH; Clark, DP; Clifton-Bligh, R; Sidransky, D; Ladenson, PW; Sykorova, V</td>
<td valign="middle" align="left">Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer</td>
<td valign="middle" align="left">JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION</td>
<td valign="middle" align="left">701</td>
<td valign="middle" align="left">2013</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1001/jama.2013.3190</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Ito, Y; Miyauchi, A; Kihara, M; Higashiyama, T; Kobayashi, K; Miya, A</td>
<td valign="middle" align="left">Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation</td>
<td valign="middle" align="left">THYROID</td>
<td valign="middle" align="left">555</td>
<td valign="middle" align="left">2014</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1089/thy.2013.0367</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Lundgren, CI; Hall, P; Dickman, PW; Zedenius, J</td>
<td valign="middle" align="left">Clinically significant prognostic factors for differentiated thyroid carcinoma -&#xa0;A population-based, nested case-control study</td>
<td valign="middle" align="left">CANCER</td>
<td valign="middle" align="left">545</td>
<td valign="middle" align="left">2006</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1002/cncr.21653</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Randolph, GW; Duh, QY; Heller, KS; LiVolsi, VA; Mandel, SJ; Steward, DL; Tufano, RP; Tuttle, RM</td>
<td valign="middle" align="left">The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension</td>
<td valign="middle" align="left">THYROID</td>
<td valign="middle" align="left">540</td>
<td valign="middle" align="left">2012</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1089/thy.2012.0043</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Xing, MZ; Liu, RY; Liu, XL; Murugan, AK; Zhu, GW; Zeiger, MA; Pai, S; Bishop, J</td>
<td valign="middle" align="left">BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence</td>
<td valign="middle" align="left">JOURNAL OF CLINICAL ONCOLOGY</td>
<td valign="middle" align="left">505</td>
<td valign="middle" align="left">2014</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1200/JCO.2014.55.5094</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Leboulleux, S; Rubino, C; Baudin, E; Caillou, B; Hartl, DM; Bidart, JM; Travagli, JP; Schlumberger, M</td>
<td valign="middle" align="left">Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis</td>
<td valign="middle" align="left">JOURNAL OF CLINICAL ENDOCRINOLOGY &amp; METABOLISM</td>
<td valign="middle" align="left">448</td>
<td valign="middle" align="left">2005</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1210/jc.2005-0285</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Ito, Y; Higashiyama, T; Takamura, Y; Kobayashi, K; Miya, A; Miyauchi, A</td>
<td valign="middle" align="left">Clinical Outcomes of Patients with Papillary Thyroid Carcinoma after the Detection of Distant Recurrence</td>
<td valign="middle" align="left">WORLD JOURNAL OF SURGERY</td>
<td valign="middle" align="left">417</td>
<td valign="middle" align="left">2010</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1007/s00268-010-0712-0</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Xing, MZ; Alzahrani, AS; Carson, KA; Shong, YK; Kim, TY; Viola, D; Elisei, R; Bendlov&#xe1;, B; Yip, L; Mian, C; Vianello, F; Tuttle, RM; Robenshtok, E; Fagin, JA; Puxeddu, E; Fugazzola, L; Czarniecka, A; Jarzab, B; O&#x2019;Neill, CJ; Sywak, MS; Lam, AK; Riesco-Eizaguirre, G; Santisteban, P; Nakayama, H; Clifton-Bligh, R; Tallini, G; Holt, EH; Sykorov&#xe1;, V</td>
<td valign="middle" align="left">Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer</td>
<td valign="middle" align="left">JOURNAL OF CLINICAL ONCOLOGY</td>
<td valign="middle" align="left">404</td>
<td valign="middle" align="left">2015</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1200/JCO.2014.56.8253</td>
</tr>
<tr>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Elisei, R; Ugolini, C; Viola, D; Lupi, C; Biagini, A; Giannini, R; Romei, C; Miccoli, P; Pinchera, A; Basolo, F</td>
<td valign="middle" align="left">BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma:: A 15-year median follow-up study</td>
<td valign="middle" align="left">JOURNAL OF CLINICAL ENDOCRINOLOGY &amp; METABOLISM</td>
<td valign="middle" align="left">404</td>
<td valign="middle" align="left">2008</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1210/jc.2008-0607</td>
</tr>
<tr>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Capper, D; Preusser, M; Habel, A; Sahm, F; Ackermann, U; Schindler, G; Pusch, S; Mechtersheimer, G; Zentgraf, H; von Deimling, A</td>
<td valign="middle" align="left">Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody</td>
<td valign="middle" align="left">ACTA NEUROPATHOLOGICA</td>
<td valign="middle" align="left">383</td>
<td valign="middle" align="left">2011</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1007/s00401-011-0841-z</td>
</tr>
<tr>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Adeniran, AJ; Zhu, ZW; Gandhi, M; Steward, DL; Fidler, JP; Giordano, TJ; Biddinger, PW; Nikiforov, YE</td>
<td valign="middle" align="left">Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas</td>
<td valign="middle" align="left">AMERICAN JOURNAL OF SURGICAL PATHOLOGY</td>
<td valign="middle" align="left">380</td>
<td valign="middle" align="left">2006</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1097/01.pas.0000176432.73455.1b</td>
</tr>
<tr>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Rahbari, R; Zhang, LS; Kebebew, E</td>
<td valign="middle" align="left">Thyroid cancer gender disparity</td>
<td valign="middle" align="left">FUTURE ONCOLOGY</td>
<td valign="middle" align="left">326</td>
<td valign="middle" align="left">2010</td>
<td valign="middle" align="left">Review</td>
<td valign="middle" align="left">10.2217/FON.10.127</td>
</tr>
<tr>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Lupi, C; Giannini, R; Ugolini, C; Proietti, A; Berti, P; Minuto, M; Materazzi, G; Elisei, R; Santoro, M; Miccoli, P; Basolo, F</td>
<td valign="middle" align="left">Extensive clinical experience - Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma</td>
<td valign="middle" align="left">JOURNAL OF CLINICAL ENDOCRINOLOGY &amp; METABOLISM</td>
<td valign="middle" align="left">326</td>
<td valign="middle" align="left">2007</td>
<td valign="middle" align="left">Article</td>
<td valign="middle" align="left">10.1210/jc.2007-1179</td>
</tr>
</tbody>
</table>
</table-wrap>
<p><xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8A</bold></xref> illustrates the co-citation patterns of the literature related to PTC prognosis. By connecting clusters, it delineates the developmental and evolving sequence of core concepts within these highly cited publications. The largest cluster, labeled as #0 nomogram, is noteworthy as it is the latest-formed cluster in the graph and its connections extend to multiple clusters, indicating that research on PTC prognosis from this perspective has emerged and evolved as an important research direction since the early 21st century, integrating and developing various research contents over time. Key concepts influencing this cluster include #4 TNM (TNM Classification of Malignant Tumors), #3 NIFTP (Noninvasive follicular thyroid neoplasm with papillary), #2 BRAF, and #1 thyroidectomy. In terms of the overall developmental trend of research content, the early concept #15 staging gradually materializes into the more mature #4 TNM. Research on PTC has evolved from # childhood PTC and early surgical treatment methods # thyroidectomy to delving deeper into the disease mechanisms, mainly based on #2 BRAF as a therapeutic target for developing novel intervention strategies.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Highly cited references co-citation network mapping of PTC prognosis from 2004 to 2024. <bold>(A)</bold> The keyword heatmap displays topics, with smaller numbers indicating larger clusters, and #0 representing the largest cluster. Node size reflects co-citation frequency, and the links between nodes signify co-citation relationships. <bold>(B)</bold> The diagram illustrates the 25 primary references characterized by pronounced bursts of citations, denoted by red spikes on the timeline. These spikes signify sudden surges in citation counts, signaling pivotal moments of emerging crucial questions or solutions within the field.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1657719-g008.tif">
<alt-text content-type="machine-generated">Network visualization titled &#x201c;A&#x201d; displays clusters of nodes connected by curved lines, each representing key research topics such as thyroidectomy, braf, childhood papillary thyroid cancer, and nomogram, color-coded for distinct themes. Below, graphic &#x201c;B&#x201d; lists the top twenty-five references with the strongest citation bursts, including publication year, citation strength, burst duration, and a horizontal bar chart visually indicating the intensity and time period of each citation burst from two thousand four to two thousand twenty-four.</alt-text>
</graphic></fig>
<p><xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8B</bold></xref> illustrates the reference with the highest burst intensity, which is the work by Haugen BR, published in 2016. Titled &#x201c;2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer&#x201d; (<xref ref-type="bibr" rid="B25">25</xref>), it has a burst intensity of 163.16. One year after publication, this reference gained widespread attention and continues to attract significant interest (2017&#x2013;2021). Cooper DS&#x2019;s work, published in 2009 and titled &#x201c;Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer&#x201d; (<xref ref-type="bibr" rid="B8">8</xref>), follows closely with a burst intensity of 95.42. Furthermore, the relatively recent references &#x201c;Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up&#x201d; (<xref ref-type="bibr" rid="B9">9</xref>) by Filetti S et&#xa0;al. and &#x201c;Overview of the 2022 WHO Classification of Thyroid Neoplasms&#x201d; (<xref ref-type="bibr" rid="B26">26</xref>) by Baloch ZW et&#xa0;al., are still experiencing bursts, indicating the ongoing interest and impact of these articles.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>In this study, we conducted a bibliometric analysis of 3,430 articles related to the prognosis of PTC sourced from the Web of Science Core Collection database. Over the past two decades, we have observed a yearly increase in the number of studies focused on PTC prognosis. This trend indicates a growing recognition among international scholars of the importance of evaluating the prognosis of PTC, rather than solely focusing on treatment. In 2022, the number of publications and citations on PTC prognosis reached an all-time high. However, our analysis of publication and citation trends revealed periods of plateau in the number of articles and citations related to PTC prognosis in recent years. One possible explanation for these plateaus could be the influence of key issues within the academic community, such as the debate surrounding thyroid cancer overdiagnosis and overtreatment. Over the past few years, the potential for overdiagnosis of thyroid cancer has been increasingly recognized (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). This might lead to a reevaluation of treatment strategies, with a shift towards more conservative approaches in certain cases. Such shifts in clinical practice and research focus can result in a temporary slowdown in publication activity as researchers and clinicians reassess existing knowledge and practices. Understanding these dynamics is crucial for interpreting the trends observed in our study and highlights the importance of aligning research efforts with evolving clinical needs and priorities. Bibliometric research specifically targeting PTC prognosis remains limited, highlighting the need for our supplementary study. Through our analysis, we aimed to assist clinicians in precisely understanding current research hotspots and trends in PTC prognosis, thereby improving patient quality of life and the quality of medical services.</p>
<p>China and the United States lead in both the volume of publications and the number of citations in this field. Although China has a higher total publication volume, the citation rate is slightly lower than that of the United States, likely due to differences in the duration and international recognition of research in this area between the two countries. Other countries, such as South Korea, Italy, and Japan, have also made significant contributions. We generated a chord diagram to illustrate the collaboration intensity among different countries in this field. It is evident that the United States collaborates closely with China and Italy, and South Korea plays a positive role in collaboration, particularly with the United States. This suggests that leading countries in this field tend to have stronger collaborations with each other, whereas cooperation with other countries is less frequent. Compared with developed countries, most developing countries have less research in this area. Similar patterns are observed among authors, with top-ranking authors primarily from South Korea, Japan, the United States, and China, and most collaborations occurring within the same country and institution. Therefore, there is a need to enhance international collaboration in this field to bridge the research gap among countries.</p>
<p>As issues related to PTC prognosis continue to emerge, various institutions from different countries have gradually begun related research. We ranked institutions based on the number of publications and total citations in this field. Our research revealed that Japan&#x2019;s Kuma Hospital, South Korea&#x2019;s Yonsei University, and China&#x2019;s Shanghai Jiao Tong University are the top three institutions in terms of publication volume, indicating a high level of attention and more comprehensive clinical data and in-depth research in PTC prognosis. Among the top ten institutions in terms of publication volume, half are from China, demonstrating China&#x2019;s significant contribution to this field. Additionally, we visualized the collaborative relationships among institutions. Spatially, institutions from the United States and European countries exhibit much tighter collaboration, far exceeding their cooperation with institutions from other regions. China and South Korea primarily collaborate domestically, with large clusters of institutions enhancing the closeness of domestic cooperation. From a temporal perspective, after foundational work by institutions in Europe, the United States, Japan, and South Korea, Chinese institutions have emerged as new contributors to the field of PTC prognosis in recent years, providing more comprehensive and refined content. With respect to institutional contributions, our findings indicate that certain institutions, such as Kuma Hospital in Japan, have been particularly prolific in publishing research on PTC prognosis. This concentration of research output may be attributed to several factors. First, Kuma Hospital has a well-established research infrastructure and dedicated resources for thyroid cancer research, allowing for sustained and focused investigations in this area (<xref ref-type="bibr" rid="B29">29</xref>). Additionally, the institution&#x2019;s collaborative network with other leading research centers facilitates the sharing of expertise and resources, further enhancing its research output (<xref ref-type="bibr" rid="B30">30</xref>). This clustering of research efforts at a single institution can lead to a deeper exploration of specific topics, such as active surveillance, and contribute significantly to the overall body of knowledge concerning PTC prognosis. However, it also highlights the need for broader international collaboration to ensure diverse perspectives and approaches in future research.</p>
<p>Journal analysis shows that <italic>Thyroid</italic>, <italic>Frontiers in Endocrinology</italic>, and the <italic>World Journal of Surgery</italic> are leading in publication volume, while Thyroid, the Journal of Clinical Endocrinology &amp; Metabolism, and the World Journal of Surgery lead in co-citation frequency, indicating strong competitiveness in this field. As shown in <xref ref-type="table" rid="T4"><bold>Table&#xa0;4</bold></xref>, Thyroid consistently ranks first across various metrics, reflecting its broad research and innovative ideas in PTC prognosis. <xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6</bold></xref> illustrates the different research areas wo which these journals belong, such as the <italic>Journal of Clinical Endocrinology &amp; Metabolism</italic>, <italic>Surgery</italic>, and <italic>Journal of Surgery</italic>, which are related to medicine and surgery. Meanwhile, <italic>Acta Cytologica</italic>, <italic>Tumor Biology</italic>, <italic>Endocrine Pathology</italic>, and <italic>Journal of Pathology</italic> are categorized under molecular biology, cell biology, and pathology. Journals such as the <italic>Endocrine-Related Cancer</italic>, <italic>Oncotarget</italic>, and <italic>CA: A Cancer Journal for Clinicians</italic> belong to cancer research or endocrinology, which is consistent with the dual-map overlay analysis in <xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6C</bold></xref>. Notably, combined with our chart analysis, we found that most publications on PTC prognosis are published in journals related to clinical research and surgery, indicating substantial research potential in basic fields.</p>
<p>Through our analysis of clinical studies and literature reports on PTC prognosis over the past two decades, we identified the top 20 keywords by frequency and total link strength. In addition to &#x201c;papillary thyroid carcinoma,&#x201d; &#x201c;thyroid cancer,&#x201d; and &#x201c;prognosis,&#x201d; other keywords related to the pathological features and therapeutic targets of PTC have emerged. High-frequency keywords and co-occurrence cluster analysis revealed current hotspots and major research directions. As shown in <xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7A</bold></xref>, these keywords are broadly divided into six clusters. The keyword with the highest co-occurrence strength, &#x201c;papillary thyroid carcinoma,&#x201d; is at the center. Terms related to cell and molecular biology, such as &#x201c;microRNA,&#x201d; &#x201c;proliferation,&#x201d; &#x201c;apoptosis,&#x201d; and &#x201c;biomarkers,&#x201d; are in the red cluster on the right side of the figure. Liviu Hitu et&#xa0;al. revealed the regulatory patterns of microRNAs in PTC cells, demonstrating that most microRNAs regularly expressed in normal thyroids have significant tumor-suppressive effects in PTC (<xref ref-type="bibr" rid="B31">31</xref>). Xu Yuan et&#xa0;al. reported that si-STAT3 could inhibit p-STAT3 protein expression, reduce cell proliferation and metastasis, and induce apoptosis in thyroid carcinoma following miRNA-148a overexpression (<xref ref-type="bibr" rid="B32">32</xref>). These studies highlight the importance of molecular biology in PTC treatment and prognosis.</p>
<p>The cancer-related terms like &#x201c;The Cancer Genome Atlas (TCGA),&#x201d; &#x201c;anaplastic thyroid cancer,&#x201d; and &#x201c;follicular thyroid cancer&#x201d; are in the yellow cluster at the bottom. TCGA is a large dataset containing clinical data from various human cancers and is an essential resource for cancer researchers. For PTC research, the TCGA is indispensable for understanding the disease mechanisms. Wang Yinghao&#x2019;s team used RNA-seq data from the TCGA database to identify that UNC5B-AS1 is an oncogene that regulates PTC cell proliferation, migration, and invasion (<xref ref-type="bibr" rid="B33">33</xref>). By comparing PTC-related cancer data and database analyses, we gained a more comprehensive understanding of the clinical diagnosis, treatment, and prognosis of PTC.</p>
<p>Terms associated with PTC risk factors and disease progression, such as &#x201c;risk factors,&#x201d; &#x201c;lateral lymph node metastasis,&#x201d; and &#x201c;risk stratification,&#x201d; are in the orange cluster. Zhao Hengqiang et&#xa0;al. analyzed clinical data from 721 thyroid cancer patients to identify risk factors for skip metastasis and lateral lymph node metastasis in PTC, and concluded that comprehensive central compartment dissection could reduce skip metastasis (<xref ref-type="bibr" rid="B34">34</xref>). Investigating potential risks in clinical cases to predict and mitigate postoperative complications and recurrence is a current hotspot in PTC prognosis research.</p>
<p>The green and blue clusters contain keywords related to clinical treatment. The blue cluster includes &#x201c;thyroidectomy&#x201d; and &#x201c;radioactive iodine,&#x201d; whereas the green cluster includes &#x201c;pathology,&#x201d; &#x201c;ultrasound,&#x201d; and &#x201c;fine-needle aspiration,&#x201d; which are common diagnostic and treatment methods in clinical practice. Accurate diagnosis and targeted surgical treatment are crucial for improving PTC prognosis. Thus, related clinical research is highly favored. Keywords such as &#x201c;immunohistochemistry&#x201d; and &#x201c;BRAF V600E&#x201d; are in the purple cluster. From a temporal perspective, early research hotspots focused on prognostic factors and high prevalence. In recent years, case reports and association guidelines have gained prominence.</p>
<p>Highly cited articles usually have significant academic influence and indicate research quality. The most cited articles include &#x201c;Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR,&#x201d; &#x201c;BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer,&#x201d; and &#x201c;Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer.&#x201d; All three studies involved BRAF V600E, highlighting its critical role in PTC pathogenesis and early detection. Research has shown that BRAF mutations are closely related to aggressive clinical features and poor prognosis in thyroid cancer patients (<xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>The co-citation analysis of PTC prognosis literature revealed the evolution and integration of research outcomes over time. A high citation frequency indicates that researchers&#x2019; understanding of PTC prognosis has progressed from basic concepts and methods to more mature perspectives and techniques. Finally, the analysis of burst intensity in related literature shows that most top-ranked documents are guidelines, likely due to their authoritative nature and reliable data sources, leading to sustained interest and citation.</p>
<p>There are several inherent limitations to this approach. First, we selected the Web of Science Core Collection (WOSCC) database to increase the quality of studies. This database is considered comprehensive and authoritative in the medical field, offering more accurate document type categorization than other databases (<xref ref-type="bibr" rid="B36">36</xref>). Nevertheless, the quality of the articles included in WOSCC can vary, which may introduce some bias into our findings. Second, some newly published articles that might be highly significant were not included because of the lag in publication time and were therefore not captured within our analysis period. Third, our search strategy relied on the Topic Search (TS) field, which restricts the search to titles, abstracts, and author keywords. Consequently, this approach may inadvertently exclude relevant studies where prognostic indicators are discussed extensively in the full text but are not explicitly captured in the abstract or keywords. Future systematic reviews could consider combining title/abstract/keyword searches with full-text retrieval to address this limitation. Fourth, the literature search was conducted on April 9, 2024. Therefore, studies published after this cutoff date were not included in the analysis. Given the rapid pace of research in oncology and molecular biology, the findings may not reflect the most recent developments in the field. Finally, this study included only articles written in English, potentially overlooking relevant literature in other languages.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>Through bibliometric analysis, the prognosis of PTC has emerged as a core research area. As PTC constitutes the majority of thyroid cancers, it is natural that most studies are related to PTC. Our analysis identified several important points that warrant further attention. First, the steady increase in research volume and the emergence of key clusters in areas such as molecular biology, risk factors, and clinical management highlight the growing complexity and multidisciplinary nature of PTC prognosis research. Second, the prominent role of certain institutions and journals underscores the importance of collaborative efforts in advancing knowledge in this field. Additionally, the high citation rates of articles focusing on BRAF V600E mutations suggest that genetic factors continue to be a critical area of investigation. These insights from our bibliometric analysis provide valuable directions for future research, emphasizing the need for continued exploration of genetic markers, risk stratification, and personalized treatment strategies to improve patient outcomes and the quality of prognostic care for PTC patients.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p></sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>PW: Formal analysis, Visualization, Writing &#x2013; original draft, Validation, Data curation, Software, Conceptualization. M-jW: Project administration, Validation, Writing &#x2013; review &amp; editing, Resources, Investigation, Visualization. Q-fM: Formal analysis, Data curation, Writing &#x2013; review &amp; editing, Software. S-bH: Visualization, Validation, Resources, Writing &#x2013; original draft, Software. WL: Conceptualization, Validation, Project administration, Supervision, Writing &#x2013; review &amp; editing. C-qZ: Resources, Formal analysis, Investigation, Conceptualization, Writing &#x2013; review &amp; editing. CZ: Visualization, Funding acquisition, Conceptualization, Validation, Supervision, Writing &#x2013; review &amp; editing.</p></sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Carlo</surname> <given-names>LV</given-names></name>
<name><surname>Matteo</surname> <given-names>M</given-names></name>
<name><surname>Cristina</surname> <given-names>B</given-names></name>
<name><surname>Werner</surname> <given-names>G</given-names></name>
<name><surname>Paola</surname> <given-names>B</given-names></name>
<name><surname>Fabio</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Thyroid cancer mortality and incidence: a global overview</article-title>. <source>Int J Cancer</source>. (<year>2014</year>) <volume>136</volume>:<page-range>2187&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ijc.29251</pub-id>. PMID: <pub-id pub-id-type="pmid">25284703</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Robert</surname> <given-names>LF</given-names></name>
<name><surname>Yuri</surname> <given-names>N</given-names></name>
<name><surname>Davis</surname> <given-names>T</given-names></name>
<name><surname>Raja</surname> <given-names>RS</given-names></name>
<name><surname>J Andrew</surname> <given-names>R</given-names></name>
<name><surname>Peter</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features</article-title>. <source>Head Neck</source>. (<year>2018</year>) <volume>40</volume>:<page-range>1881&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/hed.25141</pub-id>. PMID: <pub-id pub-id-type="pmid">29947030</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname> <given-names>M</given-names></name>
<name><surname>Liu</surname> <given-names>Q</given-names></name>
<name><surname>Sun</surname> <given-names>W</given-names></name>
<name><surname>Zhang</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>Crosstalk between thyroid carcinoma and tumor-correlated immune cells in the tumor microenvironment</article-title>. <source>Cancers (Basel)</source>. (<year>2023</year>) <volume>15</volume>:<fpage>2863</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers15102863</pub-id>. PMID: <pub-id pub-id-type="pmid">37345200</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Deng</surname> <given-names>YJ</given-names></name>
<name><surname>Li</surname> <given-names>HT</given-names></name>
<name><surname>Wang</surname> <given-names>M</given-names></name>
<name><surname>Li</surname> <given-names>N</given-names></name>
<name><surname>Tian</surname> <given-names>T</given-names></name>
<name><surname>Wu</surname> <given-names>YW</given-names></name>
<etal/>
</person-group>. 
<article-title>Global burden of thyroid cancer from 1990 to 2017</article-title>. <source>JAMA Netw Open</source>. (<year>2020</year>) <volume>3</volume>:<elocation-id>e208759</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8759</pub-id>. PMID: <pub-id pub-id-type="pmid">32589231</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhai</surname> <given-names>M</given-names></name>
<name><surname>Zhang</surname> <given-names>D</given-names></name>
<name><surname>Long</surname> <given-names>J</given-names></name>
<name><surname>Gong</surname> <given-names>Y</given-names></name>
<name><surname>Ye</surname> <given-names>F</given-names></name>
<name><surname>Liu</surname> <given-names>S</given-names></name>
<etal/>
</person-group>. 
<article-title>The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study</article-title>. <source>Cancer Med</source>. (<year>2021</year>) <volume>10</volume>:<page-range>4542&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cam4.3970</pub-id>. PMID: <pub-id pub-id-type="pmid">34002931</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname> <given-names>L</given-names></name>
<name><surname>Li</surname> <given-names>W</given-names></name>
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Wen</surname> <given-names>W</given-names></name>
<name><surname>Yao</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Total thyroidectomy is superior for initial treatment of thyroid cancer</article-title>. <source>Asia Pac J Clin Oncol</source>. (<year>2020</year>) <volume>17</volume>:<page-range>e170&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/ajco.13379</pub-id>. PMID: <pub-id pub-id-type="pmid">32757466</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bryan</surname> <given-names>RH</given-names></name>
</person-group>. 
<article-title>2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed</article-title>? <source>Cancer</source>. (<year>2016</year>) <volume>123</volume>:<page-range>372&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.30360</pub-id>. PMID: <pub-id pub-id-type="pmid">27741354</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>David</surname> <given-names>SC</given-names></name>
<name><surname>Gerard</surname> <given-names>MD</given-names></name>
<name><surname>Bryan</surname> <given-names>RH</given-names></name>
<name><surname>Richard</surname> <given-names>TK</given-names></name>
<name><surname>Stephanie</surname> <given-names>LL</given-names></name>
<name><surname>Susan</surname> <given-names>JM</given-names></name>
<etal/>
</person-group>. 
<article-title>Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer</article-title>. <source>Thyroid</source>. (<year>2009</year>) <volume>19</volume>:<page-range>1167&#x2013;214</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/thy.2009.0110</pub-id>. PMID: <pub-id pub-id-type="pmid">19860577</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Filetti</surname> <given-names>S</given-names></name>
<name><surname>Durante</surname> <given-names>C</given-names></name>
<name><surname>Hartl</surname> <given-names>D</given-names></name>
<name><surname>Leboulleux</surname> <given-names>S</given-names></name>
<name><surname>Locati</surname> <given-names>LD</given-names></name>
<name><surname>Newbold</surname> <given-names>K</given-names></name>
<etal/>
</person-group>. 
<article-title>Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up&#x2020;</article-title>. <source>Ann Oncol</source>. (<year>2019</year>) <volume>30</volume>:<page-range>1856&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdz400</pub-id>. PMID: <pub-id pub-id-type="pmid">31549998</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname> <given-names>XJ</given-names></name>
<name><surname>Wu</surname> <given-names>P</given-names></name>
<name><surname>Jia</surname> <given-names>X</given-names></name>
<name><surname>Dong</surname> <given-names>YM</given-names></name>
<name><surname>Zhao</surname> <given-names>CM</given-names></name>
<name><surname>Chen</surname> <given-names>NN</given-names></name>
<etal/>
</person-group>. 
<article-title>Mapping the structure of depression biomarker research: A bibliometric analysis</article-title>. <source>Front Psychiatry</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>943996</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fpsyt.2022.943996</pub-id>. PMID: <pub-id pub-id-type="pmid">36186850</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>K</given-names></name>
<name><surname>Zhang</surname> <given-names>Y</given-names></name>
<name><surname>Xing</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>H</given-names></name>
<name><surname>He</surname> <given-names>M</given-names></name>
<name><surname>Guo</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials</article-title>. <source>Discov Oncol</source>. (<year>2024</year>) <volume>15</volume>:<fpage>50</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12672-024-00904-6</pub-id>. PMID: <pub-id pub-id-type="pmid">38403820</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname> <given-names>C</given-names></name>
<name><surname>Luo</surname> <given-names>JY</given-names></name>
<name><surname>Pang</surname> <given-names>YY</given-names></name>
<name><surname>He</surname> <given-names>RQ</given-names></name>
<name><surname>Li</surname> <given-names>XJ</given-names></name>
<name><surname>Chen</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>Historical context, process, and development trends of pediatric thyroid cancer research: a bibliometric analysis</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1340872</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2024.1340872</pub-id>. PMID: <pub-id pub-id-type="pmid">38463235</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>A</given-names></name>
<name><surname>Luo</surname> <given-names>Z</given-names></name>
<name><surname>Zhang</surname> <given-names>J</given-names></name>
<name><surname>Cao</surname> <given-names>X</given-names></name>
</person-group>. 
<article-title>Emerging research themes in maternal hypothyroidism: a bibliometric exploration</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1370707</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1370707</pub-id>. PMID: <pub-id pub-id-type="pmid">38596686</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Archambault</surname> <given-names>&#xc9;</given-names></name>
<name><surname>Campbell</surname> <given-names>D</given-names></name>
<name><surname>Gingras</surname> <given-names>Y</given-names></name>
<name><surname>Larivi&#xe8;re</surname> <given-names>V</given-names></name>
</person-group>. 
<article-title>Comparing bibliometric statistics obtained from the Web of Science and Scopus</article-title>. <source>J Am Soc For Inf Sci Technol</source>. (<year>2009</year>) <volume>60</volume>:<page-range>1320&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/asi.21062</pub-id>. PMID: <pub-id pub-id-type="pmid">41837764</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhong</surname> <given-names>M</given-names></name>
<name><surname>Lin</surname> <given-names>ML</given-names></name>
</person-group>. 
<article-title>Bibliometric analysis for economy in COVID-19 pandemic</article-title>. <source>Heliyon</source>. (<year>2022</year>) <volume>8</volume>:<elocation-id>e10757</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e10757</pub-id>. PMID: <pub-id pub-id-type="pmid">36185135</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Saif Aldeen</surname> <given-names>SA</given-names></name>
<name><surname>Lna</surname> <given-names>WM</given-names></name>
<name><surname>Shaher</surname> <given-names>MM</given-names></name>
</person-group>. 
<article-title>Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases</article-title>. <source>J Vis Exp</source>. (<year>2019</year>). doi:&#xa0;<pub-id pub-id-type="doi">10.3791/58494</pub-id>. PMID: <pub-id pub-id-type="pmid">31710021</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>He</surname> <given-names>Z</given-names></name>
<name><surname>Zhou</surname> <given-names>B</given-names></name>
<name><surname>Feng</surname> <given-names>H</given-names></name>
<name><surname>Bai</surname> <given-names>J</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Inverted classroom teaching of physiology in basic medical education: Bibliometric visual analysis</article-title>. <source>JMIR Med Educ</source>. (<year>2024</year>) <volume>10</volume>:<elocation-id>e52224</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.2196/52224</pub-id>. PMID: <pub-id pub-id-type="pmid">38940629</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>X</given-names></name>
<name><surname>Li</surname> <given-names>Q</given-names></name>
<name><surname>Wu</surname> <given-names>L</given-names></name>
<name><surname>Xu</surname> <given-names>Z</given-names></name>
<name><surname>Yao</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Focusing on the development and current status of metamaterial absorber by bibliometric analysis</article-title>. <source>Materials (Basel)</source>. (<year>2023</year>) <volume>16</volume>:<fpage>2286</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ma16062286</pub-id>. PMID: <pub-id pub-id-type="pmid">36984166</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname> <given-names>P</given-names></name>
<name><surname>Tang</surname> <given-names>H</given-names></name>
<name><surname>Dong</surname> <given-names>Y</given-names></name>
<name><surname>Liu</surname> <given-names>K</given-names></name>
<name><surname>Jiang</surname> <given-names>P</given-names></name>
<name><surname>Liu</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>Knowledge mapping of research on land use change and food security: A visual analysis using CiteSpace and VOSviewer</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2021</year>) <volume>18</volume>:<fpage>13065</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijerph182413065</pub-id>. PMID: <pub-id pub-id-type="pmid">34948674</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Eck</surname> <given-names>NJ</given-names></name>
<name><surname>Waltman</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Software survey: VOSviewer, a computer program for bibliometric mapping</article-title>. <source>Scientometrics</source>. (<year>2010</year>) <volume>84</volume>:<page-range>523&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11192-009-0146-3</pub-id>. PMID: <pub-id pub-id-type="pmid">20585380</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Aria</surname> <given-names>M</given-names></name>
<name><surname>Cuccurullo</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>bibliometrix: An R-tool for comprehensive science mapping analysis</article-title>. <source>J Inform</source>. (<year>2017</year>) <volume>11</volume>:<page-range>959&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.joi.2017.08.007</pub-id>. PMID: <pub-id pub-id-type="pmid">41842036</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Prahallad</surname> <given-names>A</given-names></name>
<name><surname>Sun</surname> <given-names>C</given-names></name>
<name><surname>Huang</surname> <given-names>S</given-names></name>
<name><surname>Di Nicolantonio</surname> <given-names>F</given-names></name>
<name><surname>Salazar</surname> <given-names>R</given-names></name>
<name><surname>Zecchin</surname> <given-names>D</given-names></name>
<etal/>
</person-group>. 
<article-title>Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</article-title>. <source>Nature</source>. (<year>2012</year>) <volume>483</volume>:<page-range>100&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature10868</pub-id>. PMID: <pub-id pub-id-type="pmid">22281684</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xing</surname> <given-names>M</given-names></name>
<name><surname>Westra</surname> <given-names>WH</given-names></name>
<name><surname>Tufano</surname> <given-names>RP</given-names></name>
<name><surname>Cohen</surname> <given-names>Y</given-names></name>
<name><surname>Rosenbaum</surname> <given-names>E</given-names></name>
<name><surname>Rhoden</surname> <given-names>KJ</given-names></name>
<etal/>
</person-group>. 
<article-title>BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2005</year>) <volume>90</volume>:<page-range>6373&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/jc.2005-0987</pub-id>. PMID: <pub-id pub-id-type="pmid">16174717</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xing</surname> <given-names>M</given-names></name>
<name><surname>Alzahrani</surname> <given-names>AS</given-names></name>
<name><surname>Carson</surname> <given-names>KA</given-names></name>
<name><surname>Viola</surname> <given-names>D</given-names></name>
<name><surname>Elisei</surname> <given-names>R</given-names></name>
<name><surname>Bendlova</surname> <given-names>B</given-names></name>
<etal/>
</person-group>. 
<article-title>Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer</article-title>. <source>JAMA</source>. (<year>2013</year>) <volume>309</volume>:<page-range>1493&#x2013;501</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2013.3190</pub-id>. PMID: <pub-id pub-id-type="pmid">23571588</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bryan</surname> <given-names>RH</given-names></name>
<name><surname>Erik</surname> <given-names>KA</given-names></name>
<name><surname>Keith</surname> <given-names>CB</given-names></name>
<name><surname>Gerard</surname> <given-names>MD</given-names></name>
<name><surname>Susan</surname> <given-names>JM</given-names></name>
<name><surname>Yuri</surname> <given-names>EN</given-names></name>
<etal/>
</person-group>. 
<article-title>2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer</article-title>. <source>Thyroid</source>. (<year>2015</year>) <volume>26</volume>:<page-range>1&#x2013;133</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/thy.2015.0020</pub-id>. PMID: <pub-id pub-id-type="pmid">26462967</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Baloch</surname> <given-names>ZW</given-names></name>
<name><surname>Asa</surname> <given-names>SL</given-names></name>
<name><surname>Barletta</surname> <given-names>JA</given-names></name>
<name><surname>Ghossein</surname> <given-names>RA</given-names></name>
<name><surname>Juhlin</surname> <given-names>CC</given-names></name>
<name><surname>Jung</surname> <given-names>CK</given-names></name>
<etal/>
</person-group>. 
<article-title>Overview of the 2022 WHO classification of thyroid neoplasms</article-title>. <source>Endocr Pathol</source>. (<year>2022</year>) <volume>33</volume>:<page-range>27&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12022-022-09707-3</pub-id>. PMID: <pub-id pub-id-type="pmid">35288841</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Davies</surname> <given-names>L</given-names></name>
<name><surname>Welch</surname> <given-names>HG</given-names></name>
</person-group>. 
<article-title>Current thyroid cancer trends in the United States</article-title>. <source>JAMA Otolaryngol Head Neck Surg</source>. (<year>2014</year>) <volume>140</volume>:<page-range>317&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamaoto.2014.1</pub-id>. PMID: <pub-id pub-id-type="pmid">24557566</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>M</given-names></name>
<name><surname>Zheng</surname> <given-names>R</given-names></name>
<name><surname>Dal Maso</surname> <given-names>L</given-names></name>
<name><surname>Zhang</surname> <given-names>S</given-names></name>
<name><surname>Wei</surname> <given-names>W</given-names></name>
<name><surname>Vaccarella</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Mapping overdiagnosis of thyroid cancer in China</article-title>. <source>Lancet Diabetes Endocrinol</source>. (<year>2021</year>) <volume>9</volume>:<page-range>330&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s2213-8587(21)00083-8</pub-id>. PMID: <pub-id pub-id-type="pmid">33891886</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yasuhiro</surname> <given-names>I</given-names></name>
<name><surname>Akira</surname> <given-names>M</given-names></name>
<name><surname>Minoru</surname> <given-names>K</given-names></name>
<name><surname>Takuya</surname> <given-names>H</given-names></name>
<name><surname>Kaoru</surname> <given-names>K</given-names></name>
<name><surname>Akihiro</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation</article-title>. <source>Thyroid</source>. (<year>2013</year>) <volume>24</volume>:<page-range>27&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/thy.2013.0367</pub-id>. PMID: <pub-id pub-id-type="pmid">24001104</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Iwao</surname> <given-names>S</given-names></name>
<name><surname>Yasuhiro</surname> <given-names>I</given-names></name>
<name><surname>Dai</surname> <given-names>T</given-names></name>
<name><surname>Hirotaka</surname> <given-names>N</given-names></name>
<name><surname>Chie</surname> <given-names>M</given-names></name>
<name><surname>Hisakazu</surname> <given-names>S</given-names></name>
<etal/>
</person-group>. 
<article-title>Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: Consensus statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma</article-title>. <source>Thyroid</source>. (<year>2020</year>) <volume>31</volume>:<page-range>183&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/thy.2020.0330</pub-id>. PMID: <pub-id pub-id-type="pmid">33023426</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liviu</surname> <given-names>H</given-names></name>
<name><surname>Katalin</surname> <given-names>G</given-names></name>
<name><surname>Eduard-Alexandru</surname> <given-names>B</given-names></name>
<name><surname>Andra</surname> <given-names>P</given-names></name>
<name><surname>Adriana-Cezara</surname> <given-names>H</given-names></name>
<name><surname>Paul-Andrei</surname> <given-names>&#x218;</given-names></name>
<etal/>
</person-group>. 
<article-title>MicroRNA in papillary thyroid carcinoma: A systematic review from 2018 to June 2020</article-title>. <source>Cancers (Basel)</source>. (<year>2020</year>) <volume>12</volume>:<fpage>3118</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers12113118</pub-id>. PMID: <pub-id pub-id-type="pmid">33113852</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname> <given-names>Y</given-names></name>
<name><surname>Han</surname> <given-names>YF</given-names></name>
<name><surname>Zhu</surname> <given-names>SJ</given-names></name>
<name><surname>Dong</surname> <given-names>JD</given-names></name>
<name><surname>Ye</surname> <given-names>B</given-names></name>
</person-group>. 
<article-title>miRNA-148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways</article-title>. <source>Oncol Rep</source>. (<year>2017</year>) <volume>38</volume>:<page-range>3085&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/or.2017.5947</pub-id>. PMID: <pub-id pub-id-type="pmid">28901486</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<name><surname>Bhandari</surname> <given-names>A</given-names></name>
<name><surname>Niu</surname> <given-names>J</given-names></name>
<name><surname>Yang</surname> <given-names>F</given-names></name>
<name><surname>Xia</surname> <given-names>E</given-names></name>
<name><surname>Yao</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines</article-title>. <source>Hum Cell</source>. (<year>2019</year>) <volume>32</volume>:<page-range>334&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13577-019-00242-8</pub-id>. PMID: <pub-id pub-id-type="pmid">30805847</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>H</given-names></name>
<name><surname>Huang</surname> <given-names>T</given-names></name>
<name><surname>Li</surname> <given-names>H</given-names></name>
</person-group>. 
<article-title>Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer</article-title>. <source>Surgery</source>. (<year>2019</year>) <volume>166</volume>:<page-range>55&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.surg.2019.01.025</pub-id>. PMID: <pub-id pub-id-type="pmid">30876667</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>C</given-names></name>
<name><surname>Chen</surname> <given-names>T</given-names></name>
<name><surname>Liu</surname> <given-names>Z</given-names></name>
</person-group>. 
<article-title>Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis</article-title>. <source>World J Surg Oncol</source>. (<year>2016</year>) <volume>14</volume>:<fpage>241</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12957-016-0979-1</pub-id>. PMID: <pub-id pub-id-type="pmid">27600854</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yeung</surname> <given-names>AWK</given-names></name>
</person-group>. 
<article-title>Comparison between scopus, web of science, pubmed and publishers for mislabelled review papers</article-title>. <source>Curr Sci</source>. (<year>2019</year>) <volume>116</volume>:<page-range>1909&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18520/cs/v116/i11/1909-1914</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/304379">Andreas Dietz</ext-link>, Leipzig University, Germany</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1600265">Maria Luisa Garo</ext-link>, Mathsly Research, Italy</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1799566">Yantong Wan</ext-link>, Xiamen University, China</p></fn>
</fn-group>
</back>
</article>